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Abstract 
 
Introduction: Despite the Institute of Medicines recommendation that all cancer survivors 
be provided with a survivorship care plan (SCP) at the end of their treatment, very few 
cancer centers have a mechanism for doing so. One of the major obstacles for providing 
breast cancer patients SCPs is that breast cancer treatments are complex, occur over a 
variable length of time, and are provided by many different providers, thus it is difficult 
to determine when and who should provide SCPs to patients. However, the majority of 
patients diagnosed with stage I-III will receive surgery and will continue to follow up 
with their surgeon for several years following their active treatment phase. The purpose 
of this study was first to determine if it is feasible to identify women for SCPs at their 
postoperative visit and track them prospectively throughout their treatment. The 
secondary aim of this study was to determine if participant’s knowledge about their 
diagnosis, treatment, and risk for long term side effects improved after receiving their 
SCP.  
Methods: 75 English-speaking women over the age of 18 with stage I-III breast cancer 
were enrolled at their postoperative appointment.  The participants’ treatment progress 
was tracked through the electronic medical record; the treatment information was 
abstracted from the records and used to create treatment summaries. Once treatment was 
completed, participants received the SCP during one of their scheduled follow-up 
appointments. Knowledge of tumor, treatments, potential side effects, and screening 
recommendations were assessed before receiving the SCP and again two months later. 
Accuracy of responses at baseline and follow up were compared using the McNemar test. 
 
Results: Accrual occurred during 42 clinic days between April 2011 and February 2012. 
Of the patients who met the eligibility requirements 100% agreed to participate and we 
were able to complete 100% of the SCPs regardless of where participants received their 
treatments. Finally the surgical department was the only common department among all 
our participants. We found that participants were more accurate in reporting details about 
their tumor, treatments, screening recommendations, and potential side effects at follow 
up than they were at baseline for most measures but the only statistically significant 
changes were in identifying their stage (p = 0.0016), receiving 5-Fluorouracil during 
chemotherapy (p= 0.0196), and having an increased risk of leukemia (p = 0.0348).  
 
Conclusion: Women recently diagnosed with breast cancer are interested in receiving 
survivorship care plans after treatment, as demonstrated by 100% accrual rate of eligible 
patients approached in the postoperative visit. The postoperative visit in a surgical clinic 
may provide the starting point for tracking a patient through treatment. Additionally 
SCPs appear to improve patient knowledge in several important areas including basic and 
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Introduction 
 
Breast cancer is the most frequently diagnosed cancer in American women with an 
estimated 232,340 new cases of invasive breast cancer this year alone [1]. Though breast 
cancer remains the second most common cause of cancer related death among women, 
advances in screening and treatment have substantially improved breast cancer prognosis 
[1]. Currently there are 2.9 million survivors of breast cancer, which account for more 
than 40% of the female cancer survivors in the United States [1] .  
Although breast cancer survivors are cured from their cancer, many patients face long-
term side effects from their treatment. The risk of complications depends on the specific 
treatment the patient received, but many common treatments can lead to lymphedema, 
infertility, osteoporosis, cardiovascular disease, and secondary malignancies [2-5]. Both 
patients and providers should be aware of these rare but serious complications and 
monitor the patient’s health accordingly. Without universal health care records, the 
burden of recalling details of their breast cancer treatment falls largely on the patients 
after they are no longer being actively seen by their oncology team [6]. While patients are 
seen frequently by medical professionals while undergoing cancer treatment, very little 
information about the diagnosis, treatments, potential side effects, and future screening 
recommendations is written down for patients [7]. The lack of written information is 
problematic as it has been shown that many cancer patients feel overwhelmed and 
anxious during their appointments which inhibits them from absorbing and understanding 
the information [8]. Furthermore as soon as cancer patients are no longer undergoing 
active treatment their frequent visits to their oncology team stop, which can cause anxiety 
and feelings of abandonment [9]. Thus, not only can the lack of understanding of disease-
related details have potential long-term consequences on the adequacy and 
appropriateness of the survivor’s health, it can also have immediate psychological 
consequences as patients feel unprepared to handle the transition from cancer patient to 
cancer survivor [9].  These issues, coupled with the growing number of survivors, has led 
to an increased awareness from providers and policy makers of the need for standardized 
care strategies for cancer survivors that are no longer undergoing active treatment. 
In 2006 The Institute of Medicine released a report outlining ten recommendations to 
improve the care of cancer survivors [10]. One of the recommendations suggested 
practitioners provide patients with survivorship care plans (SCPs), which is thought to 
help patient’s transition from a “cancer patient” to a “cancer survivor” [10]. A 
survivorship care plan is a document summarizing information about the cancer and 
treatment. Essentially, it consists of four components, a treatment summary, information 
about potential late or long-term side effects, surveillance and healthy lifestyle 
recommendations, and identification of who will coordinate care. Though a growing 
number of comprehensive cancer treatment facilities have survivorship clinics that 
provide patients with survivorship care plans, they almost exclusively rely on physician 
or patient self- referral to survivorship clinics [11, 12]. To our knowledge there are very 
few comprehensive cancer treatment centers that report having a built-in component to 
cancer care that insures all patients will receive survivorship care plans despite the 
recommendation from the Institute of Medicine [11, 12]. Developing a strategy for 
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providing SCPs to all cancer survivors is vital, as future accreditation of hospital cancer 
programs by the Commission on Cancer of the American College of Surgeons will 
require a system for doing so, beginning in 2015 [13].  
There are several obstacles that have limited the wide dissemination of SCPs.  One 
previous barrier is that there was a lack of standardized templates. However, this 
limitation was recognized by American Society of Clinical Oncology (ASCO) who 
developed a cancer treatment template that allows providers a convenient way to store 
information about a patient’s specific treatment and The University of Pennsylvania 
Cancer Center who developed an online tool with the Livestrong Foundation that 
provides standardized care plans, which provide information on long term side effects 
and screening recommendations based on responses to treatment questions[14, 15]. One 
limitation with the ASCO tool is the level of detail is such that it requires a physician to 
complete the details of the patient’s history. The LIVESTRONG care plan is an on-line 
care plan that patients can generate themselves; however, this requires the patient to 
know which treatments they had. Studies have shown providers who have the 
information can complete the relevant questions to develop these care plans in less than 
ten minutes [16]. While the development of templates does solve a previous barrier it 
does not eliminate the need for physician’s involvement in the creation of SCPs.   
A second obstacle in providing SCPs to breast cancer patients is the diversity of treatment 
pathways. Breast cancer treatments are complex, occur over a variable length of time 
depending on the characteristics of the patient and the malignancy, and are provided by 
many different medical specialists [12]. This diversity in treatment plans and providers 
makes it difficult to systematically provide breast cancer survivors at the end of their 
treatment through a particular specialist, as this requires coordination and communication 
amongst the providers that is not always possible. However, the majority of patients 
diagnosed with stage I-III will receive surgery and will continue to follow up with their 
surgeon for several years following their active treatment phase [12]. If patients were 
open to the idea of discussing survivorship at the time of surgery, the surgical oncologist 
could serve as an ideal venue for identifying patients who will need to be given a SCP at 
the end of their treatment.  
The primary purpose of this study was to assess the feasibility of providing SCPs to 
breast cancer survivors by enrolling them at the postoperative visit and tracking them 
prospectively throughout their treatment. The secondary aim was to determine if 
participant’s knowledge about their diagnosis, treatment, and risk for long term side 
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Methods 
 
The study was conducted at Smilow Cancer Hospital at Yale-New Haven, at the Smilow 
Cancer Hospital Breast Center, a nationally accredited comprehensive breast cancer 
program. The Human Investigation Committee at Yale University approved all of the 
study procedures and documents and all participants gave written informed consent.  
Participants and Recruitment 
Participants were enrolled between April 2011 and February 2012 during their 
postoperative appointment. Female patients were eligible for the our study if they had 
pathologically confirmed stage I, II, or III breast cancer, had their breast cancer surgery at 
Smilow Cancer Hospital, and were over 18 years of age. Participants were excluded from 
participation if they were not fluent in English, or if they had a concurrent cancer 
diagnosis.  
Study Design 
Once the participant was enrolled, we began tracking their cancer treatment through the 
electronic medical record. At the end of a participant’s active treatment we reviewed the 
relevant medical records and abstracted the necessary clinical information needed to 
create treatment summaries using the ASCO template, and the Livestrong Care Plan 
generator. Participants were contacted by a research administrator as they approached the 
end of their active treatment and were scheduled for a baseline (post-treatment) interview 
that took place 15 minutes before or after an existing appointment in the cancer center. 
We defined the end of treatment as the time at which patients had completed their 
radiation and/or chemotherapy treatments and had been initiated on hormonal therapy, if 
applicable. If the patient did not receive any adjuvant therapy the end of treatment was 
defined as the appointment in which they were informed their active treatment was 
completed.  The only exception to this protocol was patients being treated with a 
yearlong course of Herceptin who could still be completing their chemotherapy at the 
time of the baseline appointment.  
During the baseline appointment participants were asked to complete three self-
administered surveys about their demographic information, medical history, and 
knowledge of the breast cancer surveillance recommendations without assistance (see 
measures). The participants were then given a written copy of their personalized care plan 
with a Yale cover letter explaining the purpose of the document. Two months after the 
baseline appointment participants were mailed the follow up questionnaires and a prepaid 
return envelope. Participants who did not return the follow-up surveys within a month of 
the mailing were contacted by telephone and were re-mailed the surveys.  
Measures 
Information on demographics, cancer diagnosis, cancer treatments, and knowledge of 
follow up recommendations was collected via the self-administered questionnaires at the 
baseline visit. The first questionnaire asked basic demographic information and included 
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questions pertaining to the participant’s age, racial/ethnic group, education, marital status, 
employment, reproductive history, and serious comorbidities.  The second questionnaire 
was used to assess the participant’s knowledge of their treatment prior to receiving the 
SCP including questions on the clinical pathology of their tumor at diagnosis, the types of 
treatment they received including questions on specific medications prescribed and dates 
that they were administered each treatment. The final questionnaire asked the participant 
specific questions about long-term side effects of breast cancer treatment, and screening 
recommendations for breast cancer survivors. In addition it asked participants to rate their 
assessment of their own knowledge about their stage, treatments, surveillance guidelines, 
and potential long-term side effects on a scale from 0 to 10 where 0 was defined as no 
knowledge and 10 was defined as expert level knowledge. The second and third 
questionnaires were also used at follow up but the third questionnaire had one additional 
question asking if the participant was satisfied with her SCP.  
Statistical Analysis 
We originally intended to characterize reasons why women choose not to enroll in our 
study, however as we enrolled all of the women who met our eligible criteria this was not 
necessary. In addition we had intended to compare the characteristics of participants who 
received their SCP to the characteristics participants who did not receive their SCP using 
chi-square analysis, t-tests, and logistic regression to determine which characteristics of 
the participant were associated with the receipt of an SCP, however we again found that 
we were able to give all of our enrolled participants an SCP. 
Analysis of the participant’s knowledge before and after the SCP was limited to 
participants who returned both the baseline and follow up surveys. The comparisons 
between participants who did not return the follow up surveys to those who did return the 
follow up surveys was done using chi-square tests for categorical variables and t tests for 
continuous variables. Responses to knowledge questions were dichotomized as correct if 
the answer was correct or incorrect if the participants choose “don’t know” or marked the 
incorrect answer. We used the McNemar test to conduct the comparison of correct 
answers chosen at baseline to those chosen at follow. 
All of our analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC) at a 
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Results 
  
We screened 129 post-operative visit diagnoses to identify eligible participants patients 
for enrollment between April 2011 and February 2012, 54 people were not eligible to 
participate due to non-invasive carcinomas (n= 46), metastatic disease (n = 3), and non-
English speaking (n = 5) (Figure 1). Of the 75 post-operative visit diagnoses that met the 
inclusion criteria, 75 patients were approached and all 75 agreed to participant, for a 
100% enrollment rate. We were able to track the treatment progress and complete the 
SCPs for all 75 participants. Further examination of the participants’ clinical pathology 
during the creation of the SCPs revealed that three of the participants did not have 
invasive breast cancer and one was unable to read in English. Though we provided these 
women with their SCPs, as these patients did not meet the eligibility requirements they 
were excluded from further evaluation. During the baseline assessment three participants 
withdrew from the study and one was released from the study due to the development of 
metastatic disease during the interim between enrolment and completion of initial therapy 
thus our final sample size was 67 women. Of the 67 eligible participants who completed 
the baseline questionnaire, 51 also completed the follow up assessment for a follow up 
rate of 76.1%. 
 
Demographic and clinical characteristics for the 51 women included in the present 
analysis are shown in Table 1. We observed that a significantly larger proportion of non-
Hispanic whites (p= 0.0014) and women with private insurance completed the follow up 
surveys (p = 0.0184). The average age at diagnosis was 56.8 years; and the predominant 
racial/ethnic group was non-Hispanic white (92.2%). The majority of our participants 
were highly educated and married. None of our participants were uninsured. 47.1% of our 
participants were diagnosed with stage I breast cancer, 37.3% with stage II, and 15.7% 
with stage III. 74.5% of our sample was ER positive, 68.6% were PR positive, 11.8% 
were HER2 positive, and 19.6% were triple negative. The majority of our sample 
received hormonal therapy (76.5%) and radiation (70.6%), whereas just over half 
(56.9%) underwent adjuvant chemotherapy. Finally 25.5% of our participants also 
attended the Survivorship Clinic at Yale Cancer Center.  
 
The accuracy of responses for tumor characteristics and treatments received at baseline 
and follow up are shown in Table 2. A greater number of participants selected correct 
responses at follow up for the majority of the questions, however the only statistically 
significant improvements in accuracy between baseline and follow up was the 
participants knowledge of their stage at diagnosis (p= 0.0016) and correct identification 
of being prescribed 5-Fluorouracil (p=0.0196). The accuracy of responses for long-term 
side effects and screening recommendations at baseline and follow up are shown in Table 
3. Again more participants choose the correct response for the long-term side effects, and 
screening recommendations at follow up than at baseline. However, the only statistically 
significant change was that more women in our sample knew that some breast cancer 
treatments increased the risk of developing Leukemia (p= 0.0348).   
 
Table 4 shows the participants perception of their own knowledge at baseline and at 
follow up. At both baseline and follow up the majority of participants reported having 
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high knowledge of their stage (60.4%, and 66.7% respectively), treatments they received 
(69.4%, and 71.4% respectively), and surveillance guidelines (61.4%, and 54.6% 
respectively). However at both baseline and follow up less than half of the participants 
reported having high knowledge of potential side effects of their treatment (50.0%, and 
42.9% respectively). There was no statistical difference in responses before and after 
receiving the SCP.  
 
The accuracy of responses of participants who attended the Survivorship Clinic at Yale 
Cancer Center was compared to the accuracy of responses of participants who did not. At 
follow up participants who attended the Survivorship Clinic were not more accurate in 
identifying details of their disease or treatment. However, participants who attended the 
Survivorship Clinic at Yale were more accurate in the identification of the treatment side 
effects including lymphedema (p= 0.0462), cardiac problems (p= 0.0225), leukemia 
(p=0.0428), neuropathy (p = 0.0302), and menopausal symptoms (p = 0.0193). Despite 
this, the participants who attended the Survivorship Clinic did not have statistically 
higher perceived knowledge at follow up.   
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Discussion 
 
Despite the Institute of Medicine’s recommendation that cancer centers provide SCPs to 
all cancer survivors, few cancer centers have systems for doing so. The primary goal of 
this study was to determine if it is feasible to identify women during their postoperative 
visit and track them prospectively through their treatment with the goal of giving a 
survivorship care plan after completion of initial treatment. Previous research suggests 
that women prefer to discuss survivorship at the end of their treatment, as they are 
already overwhelmed with information about their diagnosis and treatment options during 
their active treatment phase [17]. However, introducing survivorship during the 
postoperative visit could be advantageous, as it eliminates one of the chief logistical 
obstacles in broadly providing care plans, which is that not all breast cancer patients 
undergo the same treatment progression and thus it is difficult to identify a suitable time 
after which the provider should distribute SCPs. Though adjuvant treatment pathways 
differ between patients, nearly all breast cancer patients receive surgery and thus surgery 
clinics could provide an opportunity to identify the majority of patients who will 
eventually be cancer survivors. Moreover, like many cancer centers, at Yale breast cancer 
patients are recommended to follow up with their surgical providers every 6 months for 
the first 3 years, and every year thereafter until 5 years post operative suggesting that 
surgical clinics may be the ideal place to provide patients with completed SCPs after their 
active treatment [18].  
 
In this study we demonstrated women are open and interested in survivorship care plans 
even moments after they have learned the details of their diagnosis and potential 
treatments, as demonstrated by 100% accrual rate of eligible patients approached in the 
postoperative visit. Our sample population had a wide range of treatments, 70.6% 
received radiation, 56.9% received chemotherapy, and only 47.1% received both. 
Therefore, the surgical office is the only common setting to which every woman with 
early stage breast cancer is guaranteed to be seen. Consequently, the postoperative visit in 
a surgical clinic appears to be a viable option to start tracking a patient through treatment, 
which in turn may provide a feasible model for delivering survivorship care plans to all 
breast cancer survivors. Though this study has demonstrated the patient’s willingness to 
discuss survivorship in their post-operative appoints further research is needed to 
determine the cost effectiveness of a SCP system in the surgical clinic compared to other 
models like stand-alone survivorship clinics.  
  
The secondary goal of this study was to determine if SCPs had an effect on the patients 
knowledge about their diagnosis, treatments, and risk of long-term complications. We 
found that participant’s knowledge improved after they received their SCPs, however 
only a few of these changes were statistically significant. There have been two other 
recent studies that have explored the effectiveness of SCPs on breast cancer survivor’s 
knowledge, one of which found them to be effective and one of which found them to be 
ineffective [19, 20]. While both studies had methodological constraints the Grunfeld et al 
finding that SCPs were not effective has been heavily criticized as both the intervention 
and control groups were given similar information, thus it did not truly compare the 
effectiveness of SCPs[21, 22].  Our findings add the evidence and suggest that SCPs are 
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an effective method of improving cancer survivor’s knowledge.  Given the inconsistency 
in findings as well as the scarcity of studies further investigation is needed to determine 
the effectiveness of SCPs. However, if SCPs are found to have even a moderate effect on 
knowledge this could have significant implications in survivor’s health at a minimal cost.   
 
At both baseline and follow up women felt that they were well informed on most cancer 
related topics with over half reporting high levels of knowledge on their stage, treatments 
received, and surveillance guidelines even though they were not accurate in reporting the 
details of their treatments. This inconsistency in perceived knowledge and actual 
knowledge has potential consequences as it might prevent women from informing their 
future providers accurate information, or verifying information with their oncology 
providers. Additionally there was no statistical difference in perceived knowledge for 
stage, treatments received, surveillance guidelines, or potential side effects, but less 
women reported having high knowledge on surveillance guidelines and potential side 
effects at follow up than at baseline. Though we provided women with their SCP and 
orientated them to relative information we did not specifically point out the information 
page-by-page. We relied on the participants to read the document and ask their provider 
if they had questions or needed clarification.  Perhaps a better solution is giving a SCP 
plus dedicating time to reviewing this, essentially providing a “transition visit” where the 
information is reviewed.  
 
  
There are a few notable limitations to this study.  The first is that Smilow Cancer 
Hospital has a survivorship clinic, which is available to all patients who are interested in 
receiving survivorship care at the end of their treatment. 25.5% of our participants also 
participated in the clinic between baseline and follow up. Attending the survivorship 
Clinic may have influenced these participants knowledge who had higher levels of 
knowledge on some metrics at follow up, however these women also had a high 
knowledge at baseline suggesting that healthier, more educated women seek out the 
survivorship clinic. A second limitation is that we collected information in a single health 
care system that serves a largely Caucasian, highly educated, and insured population. It 
may be difficult to generalize these findings to a different population.  Finally as this was 
a feasibility study we did not have a control group, future studies should randomize 
patients to receive a SCP or to usual care to determine if the SCP is more useful than the 
current system. 
 
To our knowledge this is the first study to demonstrate the effectiveness of approaching 
women for SCPs in their postoperative appointment, and one of the few studies that have 
examined the effectiveness of SCPs on patient knowledge. The strengths of this study are 
that we were able to show that patients are receptive to survivorship care as soon as their 
postoperative appointments. Identifying patients for survivorship following their 
operation could significantly increase the number of patients who receive SCPs in 
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Table 1: Baseline demographics and clinical characteristics of study participants included in the 
analysis compared with those not included 
 
Entire Sample n=67  Complete Data n=51 P value† 
Age, years 
   Mean ± SD 55.9 ± 12.6 56.8 ± 12.5 0.2747 
Race/Ethnicity 
   Non-Hispanic white 56 (83.6%) 47 (92.2%) 
0.0014 Non-Hispanic black 3 (4.5%) 0 (0.0%) 
Hispanic/Latino 2 (3.0%) 1 (2.0%) 
Other 6 (9.0%) 3 (5.9%) 
Education 
   Less than high school diploma 4 (6.0%) 1 (2.0%) 
0.1509 
High school diploma 9 (13.4%) 6 (11.8%) 
Some college 14 (20.9%) 11 (21.6%) 
Baccalaureate Degree 17 (25.4%) 14 (27.5%) 
Professional or Graduate Degree 23 (34.3%) 20 (37.3%) 
Marital status 
   Single 6 (9.0%) 4 (7.8%) 
0.2419 Married/cohabiting 41 (61.2%) 34 (66.7%) Widow 8 (11.9%) 6 (11.8%) 
Separated/divorced 12 (17.9%) 7 (13.7%) 
Insurance 
   Private Insurance 40 (60.6%) 34 (68.0%) 
0.0184 Public Insurance 26 (39.4%) 16 (32.0%) 
Uninsured  0 (0.0%) 0 (0.0%) 
Disease stage 
   Stage I 32 (47.1%) 24 (47.1%) 
0.8619 Stage II 25 (36.8%) 19 (37.3%) 
Stage III 11 (16.2%) 8 (15.7%) 
Type of Treatment 
   Radiation 43 (65.2%) 36 (70.6%) 0.1215 
Chemotherapy 36 (53.7%) 29 (56.9%) 0.3956 
Hormonal therapy 52 (77.6%) 39 (76.5%) 1.0000 
Hormone Receptor Status 
   Estrogen Receptor  51 (76.1%) 38 (74.5%) 0.7429 
Progesterone Receptor  47 (70.2%) 35 (68.6%) 0.7597 
HER2  8 (11.9%) 6 (11.8%) 1.0000 
Triple Negative  12 (17.9%) 10 (19.6%) 0.7159 
Attended Yale Survivorship Clinic 
   Yes 16 (23.9%) 13 (25.5%) 0.7429 
No 51 (76.1%) 38 (74.5%) 
*Numbers may not sum due to missing data, and percentages may not sum to 100% due to rounding. 
† P-value for t-test for continuous variables χ2 test for categorical variables. 






Table 2: Accuracy of knowledge of basic and specific treatment details at baseline and follow up  
Basic Treatment Information  Baseline Follow Up P value† 
Stage 
   Accurate 37 (72.6%) 47 (92.2%) 0.0016 Inaccurate 14 (27.5%) 4 (7.8%) 
Radiation (y/n) 
   Accurate 51 (100%) 51 (100%) n/a Inaccurate 0 (0.0%) 0 (0.0%) 
Chemotherapy (y/n) 
   Accurate 51 (98.1%) 51 (98.1%) n/a Inaccurate 1 (1.9%) 1 (1.9%) 
Hormone Therapy (y/n) 
   Accurate 35 (68.6%) 41 (80.4%) 0.0833 Inaccurate 16 (31.4%) 10 (19.6%) 
Specific Treatment Information 
5- Fluorouracil 
   Accurate 19 (65.5%) 26 (89.7%) 0.0196 Inaccurate  10 (34.5%) 3 (10.3%) 
Cyclophosphamide 
   Accurate 21 (72.4%) 23 (79.3%) 0.4142 Inaccurate  8 (27.6%) 6 (20.7%) 
Methotrexate 
   Accurate 21 (72.4%) 25 (86.2%) 0.1573 Inaccurate  8 (27.6%) 4 (13.8%) 
Anthracyclines 
   Accurate 20 (69.0%) 22 (75.9%) 0.4142 Inaccurate  9 (31.0%) 7 (24.1%) 
Carboplatin 
   Accurate 21 (72.4%) 25 (86.2%) 0.1025 Inaccurate  8 (27.6%) 4 (13.8%) 
Taxanes 
   Accurate 25 (86.2%) 24 (82.8%) 0.6547 Inaccurate  4 (13.8%) 5 (17.2%) 
Tamoxifen 
   Accurate 46 (90.2%) 47 (92.2%) 0.5637 Inaccurate  5 (9.8%) 4 (7.8%) 
Anastrozole 
   Accurate 46 (90.2%) 49 (96.1%) 0.1797 Inaccurate  5 (9.8%) 2 (3.9%) 
Letrozole 
   Accurate 46 (90.2%) 47 (92.2%) 
0.6547 Inaccurate  5 (9.8%) 4 (7.8%) 
Aromasin 
   Accurate 48 (94.1%) 49 (96.1%) 0.5637 Inaccurate  3 (5.9%) 2 (3.9%) 
*Numbers may not sum to 51 as some participants did not receive each therapy, and percentages may not sum to 100% due to rounding. 
† P value for McNemar test. 
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Table 3: Accuracy of knowledge of screening recommendations and side effects at baseline and follow up 
 
Baseline Follow up  P value† 
How often should you see your oncologist  
   Correct 33 (64.7%) 37 (72.6%) 0.3458 Wrong 18 (35.3%) 14 (27.5%) 
Frequency of Mammograms  
   Correct 24 (47.1%) 28 (54.9%) 0.3938 Wrong 27 (52.9%) 23 (45.1%) 
Potential Side Effects 
   Lymphedema 
   Yes 35 (71.4%) 40 (83.3%) 
0.0956 No  7 (14.3%) 4 (8.3%) 
Do Not Know 7 (14.3%) 4 (8.3%) 
Bone Loss 
   Yes 33 (67.4%) 34 (69.4%) 
0.7815 No  7 (14.3) 8 (16.3%) 
Do Not Know 9 (18.4%) 7 (14.3%) 
Infertility 
   Yes 22 (45.8%) 24 (50.0%) 
0.5271 No  15 (31.3%) 13 (27.1%) 
Do Not Know 11 (22.9%) 11 (22.9%) 
Cardiac Problems 
   Yes 21 (43.8%) 24 (50.0%) 
0.3657 No  14 (29.2%) 13 (27.1%) 
Do Not Know 13 (27.1%) 11 (22.9%) 
Fatigue 
   Yes 40 (80.0%) 42 (87.5%) 
0.5271 No  6 (12.0%) 4 (8.3%) 
Do Not Know 4 (8.0%) 2 (4.2%) 
Leukemia or blood cancer 
   Yes 18 (36.0%) 23 (46.9%) 
0.0348 No  16 (32.0%) 16 (32.7%) 
Do Not Know 16 (32.0%)  10 (20.4%) 
Neuropathy 
   Yes 20 (40.0%) 26 (54.2%) 
0.1088 No  14 (28.0%) 10 (20.8%) 
Do Not Know 16 (32.0%) 12 (25.0%) 
Limb Swelling 
   Yes 28 (56.0%) 34 (70.8%) 
0.1336 No  11 (22.0%) 4 (8.2%) 
Do Not Know 11 (22.0%) 10 (20.8%) 
Nerve Damage 
   Yes 21 (42.0%) 25 (55.6%) 
0.2850 No  15 (30.0%) 8 (17.8%) 
Do Not Know 15 (28.0%) 12 (26.7%) 
Menopausal Symptoms 
   Yes 33 (67.4%) 33 (67.4%) 
1.0000 No  8 (16.3%) 9 (18.4%) 
Do Not Know 8 (16.3%) 7 (14.3%) 
*Numbers may not sum to 51 due to missing data, and percentages may not sum to 100% due to rounding. † P value for McNemar test. 
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Table 4: Perceived knowledge at baseline and follow up 
 
Baseline Follow up  P value† 
Stage 
   High 29 (60.4%) 32 (66.7%) 
0.6594 Medium 15 (31.3%) 11 (22.9%) 
Low 4 (8.3%) 5 (10.4%) 
Treatments Received 
   High 35 (71.4%) 35 (71.4%) 
0.7212 Medium 10 (20.4%) 12 (24.5%) 
Low 4 (8.2%) 2 (4.1%) 
Surveillance Guidelines 
   High 27 (55.1%) 26 (53.1%) 
0.2474 Medium 14 (28.6%) 20 (40.8%) 
Low 8 (16.3%) 3 (6.1%) 
Potential Side Effects 
   High 24 (48.9%) 21 (42.9%) 
0.2504 Medium 16 (32.7%) 23 (46.9%) 
Low 9 (18.4%) 5 (10.2%) 
† P value for McNemar test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
